


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:14Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407216" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407216</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>eid</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id><journal-id journal-id-type="pmc-domain-id">782</journal-id><journal-id journal-id-type="pmc-domain">eid</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407216</article-id><article-id pub-id-type="pmcid-ver">PMC12407216.1</article-id><article-id pub-id-type="pmcaid">12407216</article-id><article-id pub-id-type="pmcaiid">12407216</article-id><article-id pub-id-type="pmid">40866794</article-id><article-id pub-id-type="doi">10.3201/eid3109.250245</article-id><article-id pub-id-type="publisher-id">25-0245</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>Severe Group A <italic toggle="yes">Streptococcus</italic> Infection among Children, France, 2022&#8211;2024</subject></subj-group></article-categories><title-group><article-title>Severe Group A <italic toggle="yes">Streptococcus</italic> Infection among Children, France, 2022&#8211;2024</article-title><alt-title alt-title-type="running-head">Running head: Severe Group A <italic toggle="yes">Streptococcus</italic> Infection, France</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Colomina</surname><given-names initials="MS">Montserrat Sierra</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Flamant</surname><given-names initials="A">Alix</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Le Balle</surname><given-names initials="G">Guillaume</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cohen</surname><given-names initials="JF">J&#233;r&#233;mie F.</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Berthomieu</surname><given-names initials="L">Lionel</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leteurtre</surname><given-names initials="S">St&#233;phane</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gillet</surname><given-names initials="Y">Yves</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Javouhey</surname><given-names initials="E">Etienne</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bechet</surname><given-names initials="S">St&#233;phane</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Levy</surname><given-names initials="C">Corinne</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cohen</surname><given-names initials="R">Robert</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ferroni</surname><given-names initials="A">Agn&#232;s</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dubois</surname><given-names initials="D">Damien</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hernandez Martinez</surname><given-names initials="MA">Miguel Angel</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Plainvert</surname><given-names initials="C">C&#233;line</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tazi</surname><given-names initials="A">Asmaa</given-names></name></contrib><contrib contrib-type="author"><collab>ISAI Study Group,<xref rid="FN1" ref-type="fn"><sup>1</sup></xref></collab></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brehin</surname><given-names initials="C">Camille</given-names></name></contrib><aff>CHU Toulouse, Toulouse, France (M. Sierra Colomina, G. Le Balle, L. Berthomieu, D. Dubois, C. Brehin); Necker-Enfants Malades Hospital, Assistance Publique-H&#244;pitaux de Paris, Paris, France (A. Flamant, J.F. Cohen, A. Ferroni); Lille University, CHU Lille, Lille, France (S. Leteurtre); Groupe Francophone de R&#233;animation et Urgences P&#233;diatriques, Lille (S. Leteurtre); CHU Lyon, Lyon, France (Y. Gillet, E. Javouhey); Association Clinique et Th&#233;rapeutique du Val de Marne, Cr&#233;teil, France (S. Bechet, C. Levy); Groupe de Pathologie Infectieuse P&#233;diatrique, Cr&#233;teil (R. Cohen); National Reference Centre for Streptococci, Assistance Publique-H&#244;pitaux de Paris, Paris Centre, H&#244;pital Cochin, Paris (M.A. Hernandez Martinez, C. Plainvert, A. Tazi) </aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Montserrat Sierra Colomina, R&#233;animation P&#233;diatrique H&#244;pital des Enfants, 330 Avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse CEDEX 09, France; email: <email xlink:href="sierracolomina.m@chu-toulouse.fr">sierracolomina.m@chu-toulouse.fr</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2025</year></pub-date><volume>31</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496169</issue-id><fpage>1698</fpage><lpage>1707</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="25-0245.pdf"/><abstract><p>Group A <italic toggle="yes">Streptococcus</italic> infections have increased in Europe since September 2022. The French Pediatric Intensive Care and French Pediatric Infectious Diseases expert groups conducted a retrospective and prospective study of children who had severe group A <italic toggle="yes">Streptococcus</italic> infections during September 1, 2022&#8211;April 1, 2024, across 34 hospitals in France. A total of 402 pediatric patients (median age 4 [interquartile range 2&#8211;7.5] years; 42% girls, 58% boys) were enrolled. Cases were characterized by a low proportion of severe skin and soft tissue infections (16%), predominance of severe upper and lower respiratory tract infections (55%), and a 3.5% case-fatality rate. In multivariate analysis, hydrocortisone, corticosteroid, and vasopressor therapies were significantly associated with major sequelae or death. Molecular analysis revealed <italic toggle="yes">emm1</italic> (73.0%) and <italic toggle="yes">emm12</italic> (10.8%) strains; the M1<sub>UK</sub> clone represented 50% of <italic toggle="yes">emm1</italic> strains. Clinicians, researchers, and public health authorities must collaborate to mitigate the effects of GAS on child health.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>group A streptococcus</kwd><kwd>GAS</kwd><kwd>Streptococcus pyogenes</kwd><kwd>bacteria</kwd><kwd>streptococci</kwd><kwd>respiratory infections</kwd><kwd>invasive infection</kwd><kwd>pediatrics</kwd><kwd>France</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><italic toggle="yes">Streptococcus pyogenes</italic>, also known as group A <italic toggle="yes">Streptococcus</italic> (GAS), presents a wide spectrum of manifestations, ranging from mild infections (e.g., pharyngitis) to severe and life-threatening conditions (e.g., necrotizing fasciitis). Globally, invasive <italic toggle="yes">S. pyogenes</italic> infections (iGAS) account for nearly 2 million cases per year worldwide; the effects of those infections on young children and older adults are substantial, including a case-fatality rate of up to 20%. In late 2022 and early 2023, a surge in pediatric GAS infections garnered international attention, prompting public health agencies to issue alerts. This rise extended beyond benign cases, also encompassing a notable increase in iGAS cases (<xref rid="R1" ref-type="bibr"><italic toggle="yes">1</italic></xref>&#8211;<xref rid="R14" ref-type="bibr"><italic toggle="yes">14</italic></xref>).</p><p>In France, during the last 2 weeks of November 2022, pediatric clinicians and intensivists reported a higher than usual number of pediatric cases of iGAS to the French Public Health (Sant&#233; publique France) and the Regional Healthcare Agencies (Agences R&#233;gionales de Sant&#233;). The National Reference Center for Streptococci also observed an increase in the number of GAS strains received since the summer of 2022 compared with previous years, particularly involving strains isolated from severe pediatric cases as of the end of October 2022. Those GAS infections occurred in different regions in France and mainly in children &lt;10 years of age. In response, Sant&#233; publique France and its partners (the Groupe de Pathologie Infectieuse P&#233;diatrique, Association Clinique et Th&#233;rapeutique du Val de Marne, and the Groupe Francophone de R&#233;animation et Urgences P&#233;diatriques) have set up surveillance of these infections.</p><p>The question of the emergence of a hypervirulent GAS clone immediately arose, as did the search for risk factors associated with the most severe forms. The primary objective of this study was to describe the clinical, biological, and microbiological characteristics of pediatric severe GAS cases that occurred in France during the 2022&#8211;2023 epidemic. Our secondary objectives were to identify risk factors associated with the most severe clinical forms, describe complications and short-term outcomes, and describe the treatment and short-term management of severe pediatric GAS cases.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Study Population and Data Collection</title><p>We conducted a retrospective (September 1, 2022&#8211;December 31, 2022) and prospective (January 1, 2023&#8211;April 30, 2024) national, multicenter cohort study in 34 hospitals in France. We included all hospitalized pediatric case-patients &lt;18 years of age. </p><p>We included all cases of severe GAS infections, which included proven and probable iGAS cases. Proven iGAS was defined as per international criteria: cases in which GAS was isolated from a normally sterile site (by culture, PCR, or rapid antigen detection testing), such as blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, bone, joint/synovial fluid, or internal body site (e.g., lymph node, brain); or GAS isolated from a nonsterile site (such as a wound) and accompanied by necrotizing fasciitis or streptococcal toxic shock syndrome (<xref rid="R15" ref-type="bibr"><italic toggle="yes">15</italic></xref>). We also included probable iGAS, defined as GAS isolated from a nonsterile site such as sputum or otorhinolaryngology surgical specimens (mastoiditis, ethmoiditis, pharyngeal abscess) accompanied by <underline>&gt;</underline>1 of the following severity criteria: intravenous (IV) antibiotic drugs, surgery, or admission to the pediatric intensive care unit (PICU). Clinical data collected were demographic information (age, sex, town of residence, number of siblings, comorbidities, vaccination status, and allergies), mode of onset of illness (fever, history of viral infection within the previous 15 days), clinical manifestations, clinical evaluation upon admission, biologic and microbiological data, drug therapy, in-hospital evolution, and patient outcomes (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref>).</p></sec><sec><title>Microbiological Workup</title><p>We performed local microbiological documentation at each participating center using culture, GAS-specific PCR, 16S rDNA PCR, and antigen detection testing, as part of usual care. After inclusion of a case in the study, we sent GAS isolates to the National Reference Center for Streptococci for further characterization. Isolates were confirmed as GAS on the basis of colony morphology on horse blood agar and by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics). We determined the <italic toggle="yes">emm</italic> genotype of each strain by sequencing the variable 5&#8242; end of the <italic toggle="yes">emm</italic> gene and comparing sequences with the database of the US Centers for Disease Control and Prevention (<ext-link xlink:href="https://www2.cdc.gov/vaccines/biotech/strepblast.asp" ext-link-type="uri">https://www2.cdc.gov/vaccines/biotech/strepblast.asp</ext-link>). We also identified the toxin profile, particularly for superantigenic toxins. We performed antibiotic susceptibility testing by disc diffusion according to the European Committee on Antimicrobial Susceptibility Testing (<ext-link xlink:href="http://www.eucast.org" ext-link-type="uri">http://www.eucast.org</ext-link>). We performed a double-disc diffusion test to detect inducible resistance to clindamycin. We used PCR to detected genetic determinants of resistance to aminoglycosides; macrolides, lincosamides, and synergistins; and tetracycline, as previously described (<xref rid="R16" ref-type="bibr"><italic toggle="yes">16</italic></xref>).</p><p>We performed whole-genome sequencing on a sample of randomly selected GAS strains. We extracted genomic DNA from overnight cultures using the MasterPure Gram Positive DNA Purification kit (LGC Biosearch Technologies) according to the manufacturer&#8217;s recommendations. We sequenced the DNA using the Illumina MiSeq system. Bioinformatical analyses included identification of the M1<sub>UK</sub> clone, by recognizing its specific 27 single-nucleotide polymorphisms (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>).</p></sec><sec><title>Statistical Analysis</title><p>First, we described included cases using standard statistics. We expressed qualitative variables as frequencies and percentages and quantitative variables using the median and interquartile range (if not normally distributed). For the comparisons between groups (i.e., group without sequelae or minor sequelae vs. group with major sequelae or death; group with hospitalization in Pediatric Intermediate Care Unit [PIMCU]/PICU vs. group without hospitalization in PIMCU/PICU), we compared percentages using the &#967;<sup>2</sup> or Fisher exact test, depending on the number of patients. We compared quantitative variables using a Mann-Whitney test. We conducted all tests with a significance threshold of p&lt;0.05.</p><p>Second, to identify risk factors for the most severe cases, we performed multivariate analysis using logistic regression models. A first model aimed to identify risk factors for admission in PIMCU/PICU, and a second model focused on identifying risk factors for major sequelae or death. We included all variables with a p value &lt;0.20 on univariate analysis in the multivariable models and removed them one by one using a stepwise backward elimination approach, with a threshold of p&lt;0.05, to obtain the final models. We conducted the analyses using Stata 18 (StataCorp).</p></sec><sec><title>Ethics Statement</title><p>In accordance with France&#8217;s ethics law, patients were informed that their encoded data would be used for the study and for publication. Their nonopposition to the use of their data and publication was collected. Patients were not involved in the design of this study. This study is registered in ClinicalTrials.gov as <ext-link ext-link-type="pmc:clinical-trial" xlink:href="NCT05788861">NCT05788861</ext-link> and has been approved by the ethics review board of the Cr&#233;teil Hospital Center (Cr&#233;teil, France).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Study Population</title><p>We enrolled a total of 402 pediatric patients with severe GAS infections. Median age was 4 (interquartile range [IQR] 2&#8211;7.5) years; 42% were girls and 58% boys (<xref rid="T1" ref-type="table">Table 1</xref>; <xref rid="F1" ref-type="fig">Figures 1</xref> and <xref rid="F2" ref-type="fig">2</xref>). The most frequent comorbidities were chronic pulmonary diseases (2.2%; 9/402), notably asthma (7/9 cases). Approximately 2% of the cohort (7/402) were immunocompromised children (3 with primary immunodeficiency and 4 receiving immunosuppressive drugs). Regarding drug exposure within 7 days before admission, 8% (34/402) had recently received nonsteroidal antiinflammatory drugs (NSAIDs), 4% (17/402) had received steroids, and 25% (100/402) had received antibiotic drugs. Most GAS infections were isolated cases (81%, 326/402); 5 (1%) cases were identified as associated with collective settings, and 27 (7%) cases were linked to household clusters. A substantial percentage of children (44%) were admitted to general pediatric wards, 23% required admission to the PICU, 7% were managed in PIMCUs, and 29% were hospitalized in other specialized wards, such as neurology and surgery departments.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Clinical features of severe group A <italic toggle="yes">Streptococcus</italic> infections among 402 children, France, 2022&#8211;2024* </title></caption><table frame="hsides" rules="groups"><col width="179" span="1"/><col width="58" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Clinical features</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Median age (IQR), y<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (2&#8211;7.5)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> M</td><td valign="top" align="center" rowspan="1" colspan="1">234 (58)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> F<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">168 (42)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Comorbidities</td><td valign="top" align="center" rowspan="1" colspan="1">52 (13)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Immunosuppression<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 (2)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Viral infection in the previous 15 d</td><td valign="top" align="center" rowspan="1" colspan="1">109 (27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Influenza</td><td valign="top" align="center" rowspan="1" colspan="1">28/112 (25)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Respiratory syncytial virus</td><td valign="top" align="center" rowspan="1" colspan="1">7/112 (6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chicken pox</td><td valign="top" align="center" rowspan="1" colspan="1">37/112 (33)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SARS-CoV-2</td><td valign="top" align="center" rowspan="1" colspan="1">5/112 (4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">37/112 (33)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Isolated case</td><td valign="top" align="center" rowspan="1" colspan="1">326 (81)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Isolated fever<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">18 (4)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Site of infection</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Multiple</td><td valign="top" align="center" rowspan="1" colspan="1">146 (36)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Ear-nose-throat</td><td valign="top" align="center" rowspan="1" colspan="1">135 (34)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Skin and soft tissue</td><td valign="top" align="center" rowspan="1" colspan="1">63 (16)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bone and joint</td><td valign="top" align="center" rowspan="1" colspan="1">57 (14)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lower respiratory</td><td valign="top" align="center" rowspan="1" colspan="1">84 (21)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pleuro-pneumonia</td><td valign="top" align="center" rowspan="1" colspan="1">69 (17)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Others&#8224;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34 (8)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Septic shock&#8225;</td><td valign="top" align="center" rowspan="1" colspan="1">34 (8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Toxic rash</td><td valign="top" align="center" rowspan="1" colspan="1">37 (9)</td></tr></tbody></table><table-wrap-foot><p>*Values are no. (%) except as indicated.
&#8224;Meningitis, endocarditis, peritonitis, dental cellulitis.
&#8225;Defined as persistence of several organ failures or acute circulatory failure, failure to correct arterial hypotension despite vascular filling of <underline>&gt;</underline>40 mL/kg, or both.</p></table-wrap-foot></table-wrap><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Trends in the number of hospital admissions for severe group A <italic toggle="yes">Streptococcus</italic> infection among 402 children, by month, France, 2022&#8211;2024.</p></caption><graphic position="float" orientation="portrait" xlink:href="25-0245-F1.jpg"/></fig><fig position="float" id="F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Severe group A <italic toggle="yes">Streptococcus</italic> infection distribution in 402 children by age, France, 2022&#8211;2024.</p></caption><graphic position="float" orientation="portrait" xlink:href="25-0245-F2.jpg"/></fig><p>A total of 140 patients were &lt;3 years of age, and the most frequent clinical manifestation was ear-nose-throat (ENT) damage (<xref rid="T2" ref-type="table">Table 2</xref>; <xref rid="F3" ref-type="fig">Figure 3</xref>). One patient experienced out-of-hospital cardiac arrest, and 3% (12/402) of patients had acute respiratory distress syndrome. Acute respiratory distress was prevalent in 27% (108/402) of cases; 78% (84/108) of those were categorized as mild and 22% (24/108) as severe. During hospital stay, 3% (12/402) of patients experienced a cardio-respiratory arrest. Median C-reactive protein level at admission was 161 (IQR 76&#8211;254) mg/L (reference range 0&#8211;5 mg/L).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Management of severe group A <italic toggle="yes">Streptococcus</italic> infections among 402 children, France, 2022&#8211;2024</title></caption><table frame="hsides" rules="groups"><col width="190" span="1"/><col width="47" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Treatment</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">No. (%)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Oxygen therapy</td><td valign="top" align="center" rowspan="1" colspan="1">120 (30)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Conventional</td><td valign="top" align="center" rowspan="1" colspan="1">45 (11)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High-flow</td><td valign="top" align="center" rowspan="1" colspan="1">27 (7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Noninvasive ventilation</td><td valign="top" align="center" rowspan="1" colspan="1">11 (3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Invasive ventilation</td><td valign="top" align="center" rowspan="1" colspan="1">32 (8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Extracorporeal membrane oxygenation<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (1)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hemodynamic therapy</td><td valign="top" align="center" rowspan="1" colspan="1">97 (24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fluid resuscitation</td><td valign="top" align="center" rowspan="1" colspan="1">97 (24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vasopressor treatment<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50 (12)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">First-line antibiotic treatment</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Amoxicillin/clavulanate</td><td valign="top" align="center" rowspan="1" colspan="1">138 (34)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Third generation cephalosporin</td><td valign="top" align="center" rowspan="1" colspan="1">141 (35)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#946;-lactam + clindamycin<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">173 (43)<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjunctive therapies</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Intravenous Immunoglobulins</td><td valign="top" align="center" rowspan="1" colspan="1">17 (4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hydrocortisone hemisuccinate for shock</td><td valign="top" align="center" rowspan="1" colspan="1">19 (4)</td></tr></tbody></table></table-wrap><fig position="float" id="F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>Distribution of severe group A <italic toggle="yes">Streptococcus</italic> infection in 402 children, by type of infection and age, France, 2022&#8211;2024. ENT, ear-nose-throat.</p></caption><graphic position="float" orientation="portrait" xlink:href="25-0245-F3.jpg"/></fig><p>Nearly half of patients (44% [177/402]) required surgical intervention during their hospital stay; causes consisted of ENT drainage in 41% (73/177), osteoarticular drainage in 24% (43/402), and deep tissue abscess drainage in 6% (23/177) of cases (<xref rid="T2" ref-type="table">Table 2</xref>). Surgical intervention within the first 24 hours was necessary in 29% (117/402) of cases, primarily for procedures such as deep tissue pus drainage and joint drainage. Median duration of hospital stay was 7 (IQR 3&#8211;12) days.</p></sec><sec><title>Bacterial Data</title><p>Rapid antigen detection tests showed high positivity rates when performed; results were positive for 79% (110/139) of throat samples, 70% (48/69) of pleural effusion samples, and 39% (13/33) of cutaneous samples. PCR testing identified GAS DNA in 14% of cases, predominantly in pleural effusion fluid (38%, 22/58), followed by deep tissue abscesses (especially from ear, nose, and throat area) (32%, 19/58). GAS culture yielded positive results in 71% (285/402) of cases; GAS was isolated from blood cultures in 21% (84/402) of cases.</p><p>A total of 149 GAS isolates were sent to the National Reference Center for Streptococci (<xref rid="T3" ref-type="table">Table 3</xref>), of which 148 underwent <italic toggle="yes">emm</italic> typing. The <italic toggle="yes">emm1</italic> (73.0%, 108/148) and <italic toggle="yes">emm12</italic> (10.8%; 16/148) genotypes represented most strains. Resistance to macrolides (defined by erythromycin resistance) was found in 3% (5/148) of GAS strains. All macrolide-resistant isolates were also resistant to clindamycin.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>Molecular characterization of 149 <italic toggle="yes">Streptococcus pyogenes</italic> isolates analyzed at the French National Reference Center for Streptococci in study of children with severe group A <italic toggle="yes">Streptococcus</italic> infections, France, 2022&#8211;2024</title></caption><table frame="hsides" rules="groups"><col width="137" span="1"/><col width="99" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No. (%)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Superantigen genes</td><td valign="top" align="center" rowspan="1" colspan="1">148</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SpeA</td><td valign="top" align="center" rowspan="1" colspan="1">110 (74.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SpeB</td><td valign="top" align="center" rowspan="1" colspan="1">148 (100)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SpeC</td><td valign="top" align="center" rowspan="1" colspan="1">76 (51.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> SmeZ</td><td valign="top" align="center" rowspan="1" colspan="1">146 (98.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sic*</td><td valign="top" align="center" rowspan="1" colspan="1">108 (73.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ssa<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (7.4)<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">emm</italic> genotypes</td><td valign="top" align="center" rowspan="1" colspan="1">148</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm1</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">108 (73.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm4</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm12</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">16 (10.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm77</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm87</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm89</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Others&#8224;</td><td valign="top" align="center" rowspan="1" colspan="1">8 (5.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Not done<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Whole-genome sequencing</td><td valign="top" align="center" rowspan="1" colspan="1">25</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic toggle="yes"> emm1</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">20</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> M1<sub>UK</sub> clone among <italic toggle="yes">emm1</italic> strains</td><td valign="top" align="center" rowspan="1" colspan="1">10</td></tr></tbody></table><table-wrap-foot><p>*Sic-like genes were not analyzed.
&#8224;Others: 1 strain of each of <italic toggle="yes">emm2</italic>, <italic toggle="yes">emm3</italic>, <italic toggle="yes">emm11</italic>, <italic toggle="yes">emm22</italic>, <italic toggle="yes">emm44</italic>, <italic toggle="yes">emm75</italic>, <italic toggle="yes">emm169</italic>, and <italic toggle="yes">emm209</italic>.</p></table-wrap-foot></table-wrap><p>We performed whole-genome sequencing on 25 of the 149 isolates received at the National Reference Center for Streptococci, including 20 <italic toggle="yes">emm1</italic> isolates. The M1<sub>UK</sub> clone represented 50.0% (10/20) of the <italic toggle="yes">emm1</italic> isolates.</p></sec><sec><title>Outcomes and Sequelae</title><p>Most (77%, 311/402) patients affected by severe GAS infections were discharged with a favorable outcome, devoid of sequelae. However, 17 (4%) patients had major sequelae (amputation/cutaneous necrosis/orthopedic sequelae [n = 7], impaired respiratory function [n = 6], neurologic deficit [n = 4]), and 14 deaths were recorded, resulting in a case-fatality rate of 3.5%.</p><p>Initial clinical factors significantly associated with hospitalization in the PICU or PIMCU in univariate analysis included age &lt;3 years, exposure to corticosteroids in the days before hospitalization, viral infection within 15 days before symptom onset, type of disease, and presence of a toxic rash (<xref rid="T4" ref-type="table">Table 4</xref>). In multivariate analysis (n = 399), factors significantly associated with hospitalization in the PICU or PIMCU consisted of viral infection within the 15 days before symptom onset (adjusted odds ratio [aOR] 2.0 [95% CI 1.2&#8211;3.4]; p = 0.007) and type of disease (bone and joint damage, aOR 0.3 [95% CI 0.1&#8211;0.8], p = 0.013; pulmonary damage, aOR 2.1 [95% CI 1.04&#8211;4.3], p = 0.037) (<xref rid="T4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><title>Univariate and multivariate analysis of factors associated with PIMCU or PICU hospitalization in children with severe group A <italic toggle="yes">Streptococcus</italic> infections, France, 2022&#8211;2024*</title></caption><table frame="hsides" rules="groups"><col width="216" span="1"/><col width="110" span="1"/><col width="119" span="1"/><col width="36" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Category</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">PIMCU/PICU hospitalization</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No PIMCU/PICU hospitalization</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Univariate analysis</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Age group, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;1</td><td valign="top" align="center" rowspan="1" colspan="1">18/117 (15.4)</td><td valign="top" align="center" rowspan="1" colspan="1">33/284 (11.6)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.031</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="center" rowspan="1" colspan="1">11/117 (9.4)</td><td valign="top" align="center" rowspan="1" colspan="1">39/284 (13.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="center" rowspan="1" colspan="1">19/117 (16.2)</td><td valign="top" align="center" rowspan="1" colspan="1">20/284 (7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3&#8211;10</td><td valign="top" align="center" rowspan="1" colspan="1">55/117 (47)</td><td valign="top" align="center" rowspan="1" colspan="1">159/284 (56)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 11&#8211;18</td><td valign="top" align="center" rowspan="1" colspan="1">14/117 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">33/284 (11.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Immunosuppression</td><td valign="top" align="center" rowspan="1" colspan="1">3/115 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">4/282 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.414</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Comorbidities</td><td valign="top" align="center" rowspan="1" colspan="1">16/116 (13.8)</td><td valign="top" align="center" rowspan="1" colspan="1">36/283 (12.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.773</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Exposure to nonsteroidal antiinflammatory drug</td><td valign="top" align="center" rowspan="1" colspan="1">13/112 (11.6)</td><td valign="top" align="center" rowspan="1" colspan="1">21/272 (7.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.223</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Exposure to steroidal antiinflammatory drug</td><td valign="top" align="center" rowspan="1" colspan="1">14/112 (12.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3/275 (1)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Viral infection in the 15 days before hospitalization</td><td valign="top" align="center" rowspan="1" colspan="1">47/109 (28.9)</td><td valign="top" align="center" rowspan="1" colspan="1">62/268 (23.1)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Type of infection</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ENT</td><td valign="top" align="center" rowspan="1" colspan="1">31/117 (26.5)</td><td valign="top" align="center" rowspan="1" colspan="1">104/284 (36.6)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pulmonary</td><td valign="top" align="center" rowspan="1" colspan="1">44/117 (37.6)</td><td valign="top" align="center" rowspan="1" colspan="1">40/284 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bone and joint</td><td valign="top" align="center" rowspan="1" colspan="1">7/117 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">50/284 (17.6)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cutaneous</td><td valign="top" align="center" rowspan="1" colspan="1">16/117 (13.7)</td><td valign="top" align="center" rowspan="1" colspan="1">47/284 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td><td valign="top" align="center" rowspan="1" colspan="1">19/117 (16.2)</td><td valign="top" align="center" rowspan="1" colspan="1">43/284 (15.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Multiple damage</td><td valign="top" align="center" rowspan="1" colspan="1">50/117 (42.7)</td><td valign="top" align="center" rowspan="1" colspan="1">96/284 (33.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.091</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Toxic rash<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17/117 (14.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20/284 (7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.019</bold>
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Multivariate analysis, adjusted odds ratio (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Viral infection in the 15 days before hospitalization</td><td colspan="2" valign="top" align="center" rowspan="1">2.02 (1.21&#8211;3.37)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Osteoarticular damage</td><td colspan="2" valign="top" align="center" rowspan="1">0.29 (0.11&#8211;0.77)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.013</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pulmonary damage</td><td colspan="2" valign="top" align="center" rowspan="1">2.11 (1.04&#8211;4.29)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.037</bold>
</td></tr></tbody></table><table-wrap-foot><p>*Values are no. (%) except as indicated. Boldface indicates significance. ENT, ear-nose-throat; PICU, pediatric intensive care unit; PIMCU, pediatric intermediate care unit. </p></table-wrap-foot></table-wrap><p>Factors significantly associated with major sequelae or death in univariate analysis were a viral infection within 15 days before symptom onset, hospitalization in PIMCU or PICU, antibiotic therapy with a &#946;-lactam combined with clindamycin, receipt of IV immunoglobulins, receipt of hydrocortisone, and receipt of vasopressor therapy (<xref rid="T5" ref-type="table">Table 5</xref>). In multivariate analysis (n = 395), only hydrocortisone, use of corticosteroids during hospitalization, and vasopressor therapy remained significantly associated with major sequelae or death (<xref rid="T4" ref-type="table">Table 4</xref>).</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><title>Univariate and multivariate analysis of factors associated with major sequelae/death in children with severe group A streptococcus infections, France, 2022&#8211;2024*</title></caption><table frame="hsides" rules="groups"><col width="226" span="1"/><col width="92" span="1"/><col width="109" span="1"/><col width="53" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Category</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Major sequelae/death </th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">No major sequelae/death </th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Univariate analysis</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female sex</td><td valign="top" align="center" rowspan="1" colspan="1">14/31 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">150/365 (41)</td><td valign="top" align="center" rowspan="1" colspan="1">0.668</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Viral infection in the 15 days before hospitalization</td><td valign="top" align="center" rowspan="1" colspan="1">16/31 (52)</td><td valign="top" align="center" rowspan="1" colspan="1">88/365 (24.1)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Clinical damage</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.094</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ENT</td><td valign="top" align="center" rowspan="1" colspan="1">8/31 (25.8)</td><td valign="top" align="center" rowspan="1" colspan="1">127/365 (34.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Pulmonary</td><td valign="top" align="center" rowspan="1" colspan="1">11/48 (35.5)</td><td valign="top" align="center" rowspan="1" colspan="1">69/365 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Osteoarticular</td><td valign="top" align="center" rowspan="1" colspan="1">3/31 (9.7)</td><td valign="top" align="center" rowspan="1" colspan="1">54/365 (14.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cutaneous</td><td valign="top" align="center" rowspan="1" colspan="1">2/31 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">60/365 (16.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td><td valign="top" align="center" rowspan="1" colspan="1">7/31 (22.6)</td><td valign="top" align="center" rowspan="1" colspan="1">55/365 (15)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> PIMCU/PICU admission</td><td valign="top" align="center" rowspan="1" colspan="1">22/31 (71)</td><td valign="top" align="center" rowspan="1" colspan="1">90/365 (24.7)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Clindamycin therapy</td><td valign="top" align="center" rowspan="1" colspan="1">21/31 (67.7)</td><td valign="top" align="center" rowspan="1" colspan="1">148/365 (40.5)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.003</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Intravenous immunoglobulins</td><td valign="top" align="center" rowspan="1" colspan="1">6/31 (19.3)</td><td valign="top" align="center" rowspan="1" colspan="1">10/355 (2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Corticosteroidal therapy</td><td valign="top" align="center" rowspan="1" colspan="1">5/28 (17.9)</td><td valign="top" align="center" rowspan="1" colspan="1">36/356 (10.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.201</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hydrocortisone hemisuccinate for shock</td><td valign="top" align="center" rowspan="1" colspan="1">12/29 (41.4)</td><td valign="top" align="center" rowspan="1" colspan="1">7/353 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vasopressive drug<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19/30 (63.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25/343 (7.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Multivariate analysis, odds ratio (95% CI)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Corticosteroidal therapy</td><td colspan="2" valign="top" align="center" rowspan="1">4.18 (1.27&#8211;13.75)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.018</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hydrocortisone hemisuccinate for shock</td><td colspan="2" valign="top" align="center" rowspan="1">6.25 (1.53&#8211;25.50)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.011</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vasopressive drug</td><td colspan="2" valign="top" align="center" rowspan="1">11.27 (3.54&#8211;35.89)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&lt;0.001</bold>
</td></tr></tbody></table><table-wrap-foot><p>*Values are no. (%) except as indicated. Boldface indicates significance. ENT, ear-nose-throat; PICU, pediatric intensive care unit; PIMCU, pediatric intermediate care unit.</p></table-wrap-foot></table-wrap><p>Genotypes <italic toggle="yes">emm1</italic> and <italic toggle="yes">emm12</italic> were not significantly associated with the risk for admission to PIMCU/PICU or the risk for persistent sequelae. Genotype <italic toggle="yes">emm1</italic> was significantly associated with respiratory damage (upper and lower) compared with other types of damage (p = 0.01).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study provides detailed characterization of severe GAS infections in pediatric patients in France. It covers a wide range of clinical data, including demographic characteristics, clinical manifestations, laboratory findings, treatment modalities, and outcomes, thereby providing a thorough understanding of the disease spectrum and its implications. Key findings include the absence of emerging GAS clones, a predominance of <italic toggle="yes">emm1</italic> and <italic toggle="yes">emm12</italic> genotypes, a case-fatality rate of 3.5%, and a predominance of upper and lower respiratory tract infections. We were also able to identify several risk factors associated with the most severe forms of GAS disease.</p><p>One third of severe infections occurred in children &lt;3 years of age, an age group in which benign GAS infections (mainly ENT-related) are considered rare, underlining the challenges of early diagnosis in this age group. The frequency of acute GAS infections peaks in childhood, but invasive infections are observed in the extreme age groups (&lt;1 and &gt;65 years of age) (<xref rid="R18" ref-type="bibr"><italic toggle="yes">18</italic></xref>). This pattern could be explained by immune system naivety in young children and immunosenescence in the elderly. The strongest evidence for the existence of protective immune responses against GAS is the observed decrease in susceptibility to infection with increasing age. The incidence of symptomatic throat infections, including scarlet fever, increases dramatically around the age of 4 (<xref rid="R19" ref-type="bibr"><italic toggle="yes">19</italic></xref>). This increase could be caused by the expansion of tonsil tissue, which enables better access to GAS; entry into school communities, with increased exposure to GAS; or simply by the ability of children of that age to verbalize sore throats. Toward the end of childhood, the frequency of streptococcal pharyngitis decreases substantially. GAS skin infections exhibit a similar peak and fall in incidence but at a slightly earlier age than throat infections, perhaps linked to a greater frequency of skin lesions in young children (<xref rid="R20" ref-type="bibr"><italic toggle="yes">20</italic></xref>).</p><p>In our cohort, clinical manifestations consisted predominately of ENT and lung infections, consistent with findings from other studies (<xref rid="R7" ref-type="bibr"><italic toggle="yes">7</italic></xref>). The 2022&#8211;23 winter in France saw exceptionally intense viral epidemics, including respiratory syncytial virus, influenza, and SARS-CoV-2, compared with previous years. Such respiratory viral infections have been associated with increased susceptibility to severe GAS infections and related ENT and pulmonary complications, suggesting a potential interplay between viruses and bacteria (<xref rid="R21" ref-type="bibr"><italic toggle="yes">21</italic></xref>,<xref rid="R22" ref-type="bibr"><italic toggle="yes">22</italic></xref>). Varicella zoster virus has also been implicated in both cutaneous and articular manifestations of iGAS infections, further supporting a potential synergistic relationship that might exacerbate disease severity (<xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>,<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>). Those findings highlight the importance of monitoring viral coinfections and their potential role in the pathogenesis of iGAS.</p><p>The concept of an immunity debt because of reduced exposure and heightened hygiene measures during COVID-19 lockdowns has been proposed to explain the resurgence in 2022&#8211;2023 of invasive bacterial infections in children, including pneumococcal, meningococcal, and pertussis infections (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>,<xref rid="R25" ref-type="bibr"><italic toggle="yes">25</italic></xref>,<xref rid="R26" ref-type="bibr"><italic toggle="yes">26</italic></xref>). Similarly, a rise in mild GAS infections in outpatient settings was reported in France before the 2022&#8211;2023 surge in severe cases (<xref rid="R2" ref-type="bibr"><italic toggle="yes">2</italic></xref>). However, our study cannot confirm this hypothesis for iGAS infections, given the absence of pre-2022 data (Appendix) and the uncertainty regarding a potential continuum between noninvasive and severe forms of the disease, despite the high incidence of severe ENT infections and pneumonia observed in our cohort (<xref rid="R23" ref-type="bibr"><italic toggle="yes">23</italic></xref>). Those considerations underscore the need for robust outpatient surveillance and appropriate use of diagnostic tools to guide GAS management. In addition, considering COVID-19 infection itself as a potential predisposing factor for iGAS is critical, as previously discussed.</p><p>The case-fatality rate of 3.5%, the elevated surgical intervention rate (44%), and the long median of hospital stay (7 days) illustrate the burden of severe GAS infections on patients, their families, and the healthcare system. Although GAS is often considered a minor pathogen responsible for mostly mild infections, the 2022&#8211;2023 worldwide epidemic reminds us that GAS possesses a full range of virulence factors that are capable of causing severe damage and must not be overlooked. In low- and-middle income settings, rheumatic fever is an additional concern. Those challenges have prompted clinicians to diagnose and treat noninvasive infections, such as pharyngitis, and has prompted researchers to develop vaccines against them. Of note, the promising 30-valent M protein&#8211;based vaccine described by Finn et al. (<xref rid="R27" ref-type="bibr"><italic toggle="yes">27</italic></xref>) includes almost all the <italic toggle="yes">emm</italic> types identified in our study. It covers the predominant <italic toggle="yes">emm</italic> types circulating in temperate regions, highlighting its potential for broad epidemiologic coverage.</p><p>Further research is needed to establish the most effective therapeutic strategies for managing iGAS infections. The role of adjunctive treatments such as clindamycin, which might help reduce GAS toxin production, and IV immunoglobulin, which might neutralize toxin activity, remains a subject of debate. A recent observational study from Japan found no significant effect of those therapies on in-hospital mortality (<xref rid="R22" ref-type="bibr"><italic toggle="yes">22</italic></xref>). In our own multivariate analysis, only the use of hydrocortisone, corticosteroids, and vasopressor therapy during hospitalization was significantly associated with major sequelae or death. However, those findings likely reflect their use in the most severely ill patients, rather than indicating a direct causal effect.</p><p>The most frequent genotypes identified in our pediatric cohort were <italic toggle="yes">emm1</italic> and <italic toggle="yes">emm12</italic>, similar to those reported in other countries during the 2022&#8211;2023 epidemic and in earlier prepandemic cohorts (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>,<xref rid="R28" ref-type="bibr"><italic toggle="yes">28</italic></xref>). However, the proportion of <italic toggle="yes">emm1</italic> strains in our series was higher than in other studies (e.g., Spain, United Kingdom, Portugal series) (<xref rid="R5" ref-type="bibr"><italic toggle="yes">5</italic></xref>,<xref rid="R29" ref-type="bibr"><italic toggle="yes">29</italic></xref>&#8211;<xref rid="R31" ref-type="bibr"><italic toggle="yes">31</italic></xref>). Of note, a recent population-based study conducted in 10 US states that included 21,312 patients (1,272 children) with invasive GAS infections during 2013&#8211;2022 documented a decline in pharyngeal strains (such as <italic toggle="yes">emm1</italic> and <italic toggle="yes">emm12</italic>) during the COVID-19 pandemic, alongside an increase in skin-associated <italic toggle="yes">emm</italic> types (<xref rid="R24" ref-type="bibr"><italic toggle="yes">24</italic></xref>). The epidemic in France confirmed the continued expansion of the M1<sub>UK</sub> clone, which has been progressively spreading since its first detection in the United Kingdom in 2008 (<xref rid="R17" ref-type="bibr"><italic toggle="yes">17</italic></xref>).</p><p>The first limitation of our study is that, despite our thorough description of the severe GAS infections observed during the 2022&#8211;2023 outbreak, the lack of a control period from the pre&#8211;COVID-19 era prevents us from drawing precise epidemiologic conclusions about changes in incidence rates over time (<xref rid="SD1" ref-type="supplementary-material">Appendix</xref>). Second, the relatively small number of isolates and the limited subset analyzed by whole-genome sequencing further restrict our ability to detect the emergence of specific strains. Finally, although this study relies on a large and nationwide network of 34 hospitals, we cannot guarantee the exhaustiveness or full representativeness of our case series.</p><p>Future research endeavors should focus on elucidating the underlying mechanisms driving the surge in pediatric severe GAS infections and the interplay between viral co-infections and bacterial complications. Comprehensive surveillance programs targeting both viral and bacterial pathogens, including GAS, are essential for early detection, timely intervention, and prevention of severe GAS disease outcomes. Furthermore, enhanced understanding of host&#8211;pathogen interactions, immune responses, genetic predispositions, and pathogen virulence that influence susceptibility to severe GAS infections is needed. Such knowledge can inform the development of targeted therapeutic approaches, including immunomodulatory strategies and vaccine development, to mitigate the burden of iGAS infections in pediatric populations.</p><p>In conclusion, pediatric severe GAS infections represent a substantial clinical and public health challenge, characterized by a high number of cases and associated illnesses and deaths during the winter of 2022&#8211;23 in several countries. This cohort in France demonstrated a high rate of respiratory diagnoses and a significant need for procedural intervention, mainly driven by <italic toggle="yes">emm1</italic> and <italic toggle="yes">emm12</italic> genotypes and the M1<sub>UK</sub> strain. Advances in diagnostic modalities, antibiotic therapy, and supportive care have improved outcomes of severe GAS infections, but continued research efforts are needed to unravel the complexities of these infections and inform evidence-based strategies for prevention, management, and surveillance. Collaboration between clinicians, researchers, and public health authorities is essential to address the evolving landscape of pediatric severe GAS infections and mitigate their effects on child health.</p></sec><sec sec-type="supplementary-material"><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><caption><title>Appendix</title><p>Additional information about severe group A <italic toggle="yes">Streptococcus</italic> infection among children, France, 2022&#8211;2024.</p></caption><media xlink:href="25-0245-Techapp-s1.pdf" id="d67e1307" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We thank the bacteriology laboratories and the ISAI study group for supporting this project. </p><p>Additional ISAI Study Group members who contributed data: Charlotte Borocco, Gerald Boussicault, Samar Armouche, Ulrike Frey, Agnes Rey, Bertrand Soto, Charlotte Pons, Marion Favier, Letitia Pantalone, Amandine Poinot, Edwige Da Zoclanclounon, Isabelle Grimal, Etienne Bizot, Etienne Merlin, Didier Chognot, Guy Ngalula, Isabelle Hau, Blandine Desse, Annie Sfez, Cyrielle Fouquerel, Eskander Eleonore, Tim&#233; Muller, Cecile Bost-Bru, Marie-Aliette Dommergues, Justine De Larminat, Delphine Penel, Fran&#231;ois Dubos, Jean Gaschinard, Aurelie Morand, Noemie Vanel, Olivier Vignaud, Marie Lamant, Julien Baleine, Constance Bridonneau, Julien Jegard, Nathalie Blot, Sandrine Baron-Joly, Anne Filleron, Marion Ashman, Ferrandiz Charl&#232;ne, Naim Ouldali, Lea Lenglart, Pauline Meslin, Laura Labro, Didier Pinquier, Tiffany Trollet, Marie-Caroline Ploton, and Anais Chosidow. </p></ack><fn-group><fn fn-type="other"><p><italic toggle="yes">Suggested citation for this article</italic>: Sierra Colomina M, Flamant A, Le Balle G, Cohen JF, Berthomieu L, Leteurtre S, et al. Severe group A <italic toggle="yes">Streptococcus</italic> infection among children, France, 2022&#8211;2024. Emerg Infect Dis. 2025 Sep [<italic toggle="yes">date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid3109.250245" ext-link-type="uri">https://doi.org/10.3201/eid3109.250245</ext-link></p></fn><fn id="FN1"><label>1</label><p>Additional members who contributed data are listed at the end of this article. </p></fn></fn-group><bio id="d67e1327"><p>Dr. Sierra Colomina is a senior pediatric critical care physician and researcher at Toulouse University Hospital, France. Her research focuses on emerging severe infectious diseases in children and their critical care management.</p></bio><ref-list><title>References</title><ref id="R1"><label>1. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Alcolea-Medina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Snell</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Alder</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Charalampous</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>TGS</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>MKI</given-names></string-name>, <etal>et al.</etal>; <collab>Synnovis Microbiology Laboratory Group</collab>. <article-title>The ongoing <italic toggle="yes">Streptococcus pyogenes</italic> (Group A <italic toggle="yes">Streptococcus</italic>) outbreak in London, United Kingdom, in December 2022: a molecular epidemiology study.</article-title><source>Clin Microbiol Infect</source>. <year>2023</year>;<volume>29</volume>:<fpage>887</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2023.03.001</pub-id><pub-id pub-id-type="pmid">36925107</pub-id><pub-id pub-id-type="pmcid">PMC10769882</pub-id></mixed-citation></ref><ref id="R2"><label>2. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cohen</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Rybak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Werner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kochert</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Cahn-Sellem</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gelbert</surname><given-names>N</given-names></string-name>, <etal>et al.</etal><article-title>Surveillance of noninvasive group A <italic toggle="yes">Streptococcus</italic> infections in French ambulatory pediatrics before and during the COVID-19 pandemic: a prospective multicenter study from 2018-2022.</article-title><source>Int J Infect Dis</source>. <year>2023</year>;<volume>134</volume>:<fpage>135</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2023.06.003</pub-id><pub-id pub-id-type="pmid">37290573</pub-id></mixed-citation></ref><ref id="R3"><label>3. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>van der Putten</surname><given-names>BCL</given-names></string-name>, <string-name name-style="western"><surname>Bril-Keijzers</surname><given-names>WCM</given-names></string-name>, <string-name name-style="western"><surname>Rumke</surname><given-names>LW</given-names></string-name>, <string-name name-style="western"><surname>Vestjens</surname><given-names>SMT</given-names></string-name>, <string-name name-style="western"><surname>Koster</surname><given-names>LAM</given-names></string-name>, <string-name name-style="western"><surname>Willemsen</surname><given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Novel <italic toggle="yes">emm</italic>4 lineage associated with an upsurge in invasive group A streptococcal disease in the Netherlands, 2022.</article-title><source>Microb Genom</source>. <year>2023</year>;<volume>9</volume>:<elocation-id>mgen001026</elocation-id>. <pub-id pub-id-type="doi">10.1099/mgen.0.001026</pub-id><pub-id pub-id-type="pmid">37261428</pub-id><pub-id pub-id-type="pmcid">PMC10327499</pub-id></mixed-citation></ref><ref id="R4"><label>4. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Johannesen</surname><given-names>TB</given-names></string-name>, <string-name name-style="western"><surname>Munkstrup</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Edslev</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Baig</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nielsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Funk</surname><given-names>T</given-names></string-name>, <etal>et al.</etal><article-title>Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent <italic toggle="yes">Streptococcus pyogenes</italic> M1 clone, Denmark, 2023.</article-title><source>Euro Surveill</source>. <year>2023</year>;<volume>28</volume>:<elocation-id>2300291</elocation-id>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2023.28.26.2300291</pub-id><pub-id pub-id-type="pmid">37382884</pub-id><pub-id pub-id-type="pmcid">PMC10311951</pub-id></mixed-citation></ref><ref id="R5"><label>5. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Guy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Henderson</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Coelho</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hughes</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mason</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Gerver</surname><given-names>SM</given-names></string-name>, <etal>et al.</etal><article-title>Increase in invasive group A streptococcal infection notifications, England, 2022.</article-title><source>Euro Surveill</source>. <year>2023</year>;<volume>28</volume>:<elocation-id>2200942</elocation-id>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2023.28.1.2200942</pub-id><pub-id pub-id-type="pmid">36695450</pub-id><pub-id pub-id-type="pmcid">PMC9817207</pub-id></mixed-citation></ref><ref id="R6"><label>6. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>de Gier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Marchal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>de Beer-Schuurman</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Te Wierik</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hooiveld</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de Melker</surname><given-names>HE</given-names></string-name>, <etal>et al.</etal>; <collab>ISIS-AR Study Group</collab>; <collab>GAS Study group</collab>; <collab>Members of the GAS study group</collab>; <collab>Members of the ISIS-AR study group</collab>. <article-title>Increase in invasive group A streptococcal (<italic toggle="yes">Streptococcus pyogenes</italic>) infections (iGAS) in young children in the Netherlands, 2022.</article-title><source>Euro Surveill</source>. <year>2023</year>;<volume>28</volume>:<elocation-id>2200941</elocation-id>. <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2023.28.1.2200941</pub-id><pub-id pub-id-type="pmid">36695447</pub-id><pub-id pub-id-type="pmcid">PMC9817208</pub-id></mixed-citation></ref><ref id="R7"><label>7. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Boeddha</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Atkins</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>de Groot</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Driessen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hazelzet</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zenz</surname><given-names>W</given-names></string-name>, <etal>et al.</etal>; <collab>EUCLIDS consortium</collab>. <article-title>Group A streptococcal disease in paediatric inpatients: a European perspective.</article-title><source>Eur J Pediatr</source>. <year>2023</year>;<volume>182</volume>:<fpage>697</fpage>&#8211;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1007/s00431-022-04718-y</pub-id><pub-id pub-id-type="pmid">36449079</pub-id><pub-id pub-id-type="pmcid">PMC9709363</pub-id></mixed-citation></ref><ref id="R8"><label>8. </label><mixed-citation publication-type="webpage"><collab>Sant&#233; Publique France</collab>. Infection invasive &#224; streptocoque du Groupe A (IISGA): point de situation au 6 d&#233;cembre <year>2022</year> [<comment>cited 2025 Feb 12</comment>]. <ext-link xlink:href="https://www.santepubliquefrance.fr/les-actualites/2022/infection-invasive-a-streptocoque-du-groupe-a-iisga-point-de-situation-au-6-decembre-2022" ext-link-type="uri">https://www.santepubliquefrance.fr/les-actualites/2022/infection-invasive-a-streptocoque-du-groupe-a-iisga-point-de-situation-au-6-decembre-2022</ext-link></mixed-citation></ref><ref id="R9"><label>9. </label><mixed-citation publication-type="webpage"><collab>World Health Organization</collab>. Increase in invasive Group A streptococcal infections among children in Europe, including fatalities [<comment>cited 2025 Feb 12</comment>]. <ext-link xlink:href="https://www.who.int/europe/news-room/12-12-2022-increase-in-invasive-group-a-streptococcal-infections-among-children-in-europe%E2%80%93including-fatalities" ext-link-type="uri">https://www.who.int/europe/news-room/12-12-2022-increase-in-invasive-group-a-streptococcal-infections-among-children-in-europe&#8211;including-fatalities</ext-link></mixed-citation></ref><ref id="R10"><label>10. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jain</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lansiaux</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Reinis</surname><given-names>A</given-names></string-name>. <article-title>Group A streptococcal (GAS) infections amongst children in Europe: Taming the rising tide.</article-title><source>New Microbes New Infect</source>. <year>2022</year>;<volume>51</volume>:<elocation-id>101071</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.nmni.2022.101071</pub-id><pub-id pub-id-type="pmid">36593885</pub-id><pub-id pub-id-type="pmcid">PMC9803947</pub-id></mixed-citation></ref><ref id="R11"><label>11. </label><mixed-citation publication-type="book">Ferretti JJ, Stevens DL, Fischetti VA, editors. <italic toggle="yes">Streptococcus pyogenes</italic>: basic biology to clinical manifestations. 2nd ed. Oklahoma City (OK): University of Oklahoma Health Sciences Center; <year>2022</year>.<pub-id pub-id-type="pmid">36479747</pub-id></mixed-citation></ref><ref id="R12"><label>12. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zachariadou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Stathi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tassios</surname><given-names>PT</given-names></string-name>, <string-name name-style="western"><surname>Pangalis</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Legakis</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Papaparaskevas</surname><given-names>J</given-names></string-name>; <collab>Hellenic Strep-Euro Study Group</collab>. <article-title>Differences in the epidemiology between paediatric and adult invasive <italic toggle="yes">Streptococcus pyogenes</italic> infections.</article-title><source>Epidemiol Infect</source>. <year>2014</year>;<volume>142</volume>:<fpage>512</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1017/S0950268813001386</pub-id><pub-id pub-id-type="pmid">23746128</pub-id><pub-id pub-id-type="pmcid">PMC9151163</pub-id></mixed-citation></ref><ref id="R13"><label>13. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Floret</surname><given-names>D</given-names></string-name>. <article-title>[Clinical aspects of streptococcal and staphylococcal toxinic diseases]</article-title><comment>[in French]</comment>. <source>Arch Pediatr</source>. <year>2001</year>;<volume>8</volume>(<issue>Suppl 4</issue>):<fpage>762s</fpage>&#8211;<lpage>8s</lpage>. <pub-id pub-id-type="doi">10.1016/S0929-693X(01)80194-9</pub-id><pub-id pub-id-type="pmid">11582925</pub-id></mixed-citation></ref><ref id="R14"><label>14. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Deniskin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shah</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Mu&#241;oz</surname><given-names>FM</given-names></string-name>, <string-name name-style="western"><surname>Flores</surname><given-names>AR</given-names></string-name>. <article-title>Clinical manifestations and bacterial genomic analysis of group A <italic toggle="yes">Streptococcus</italic> strains that cause pediatric toxic shock syndrome.</article-title><source>J Pediatric Infect Dis Soc</source>. <year>2019</year>;<volume>8</volume>:<fpage>265</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/jpids/piy069</pub-id><pub-id pub-id-type="pmid">30085250</pub-id><pub-id pub-id-type="pmcid">PMC6601382</pub-id></mixed-citation></ref><ref id="R15"><label>15. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Miller</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Lamagni</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cherian</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cannon</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Parks</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Adegbola</surname><given-names>RA</given-names></string-name>, <etal>et al.</etal><article-title>Standardization of epidemiological surveillance of invasive group A streptococcal infections.</article-title><source>Open Forum Infect Dis</source>. <year>2022</year>;<volume>9</volume>(<issue>Suppl 1</issue>):<fpage>S31</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofac281</pub-id><pub-id pub-id-type="pmid">36128405</pub-id><pub-id pub-id-type="pmcid">PMC9474937</pub-id></mixed-citation></ref><ref id="R16"><label>16. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Malhotra-Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lammens</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Piessens</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Goossens</surname><given-names>H</given-names></string-name>. <article-title>Multiplex PCR for simultaneous detection of macrolide and tetracycline resistance determinants in streptococci.</article-title><source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>:<fpage>4798</fpage>&#8211;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.49.11.4798-4800.2005</pub-id><pub-id pub-id-type="pmid">16251336</pub-id><pub-id pub-id-type="pmcid">PMC1280148</pub-id></mixed-citation></ref><ref id="R17"><label>17. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lynskey</surname><given-names>NN</given-names></string-name>, <string-name name-style="western"><surname>Jauneikaite</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Zhi</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Turner</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Mosavie</surname><given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Emergence of dominant toxigenic M1T1 <italic toggle="yes">Streptococcus pyogenes</italic> clone during increased scarlet fever activity in England: a population-based molecular epidemiological study.</article-title><source>Lancet Infect Dis</source>. <year>2019</year>;<volume>19</volume>:<fpage>1209</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(19)30446-3</pub-id><pub-id pub-id-type="pmid">31519541</pub-id><pub-id pub-id-type="pmcid">PMC6838661</pub-id></mixed-citation></ref><ref id="R18"><label>18. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Steer</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Lamagni</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Carapetis</surname><given-names>JR</given-names></string-name>. <article-title>Invasive group a streptococcal disease: epidemiology, pathogenesis and management.</article-title><source>Drugs</source>. <year>2012</year>;<volume>72</volume>:<fpage>1213</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2165/11634180-000000000-00000</pub-id><pub-id pub-id-type="pmid">22686614</pub-id><pub-id pub-id-type="pmcid">PMC7100837</pub-id></mixed-citation></ref><ref id="R19"><label>19. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lamagni</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Darenberg</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luca-Harari</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Siljander</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Efstratiou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Henriques-Normark</surname><given-names>B</given-names></string-name>, <etal>et al.</etal>; <collab>Strep-EURO Study Group</collab>. <article-title>Epidemiology of severe <italic toggle="yes">Streptococcus pyogenes</italic> disease in Europe.</article-title><source>J Clin Microbiol</source>. <year>2008</year>;<volume>46</volume>:<fpage>2359</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00422-08</pub-id><pub-id pub-id-type="pmid">18463210</pub-id><pub-id pub-id-type="pmcid">PMC2446932</pub-id></mixed-citation></ref><ref id="R20"><label>20. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Tsoi</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Smeesters</surname><given-names>PR</given-names></string-name>, <string-name name-style="western"><surname>Frost</surname><given-names>HRC</given-names></string-name>, <string-name name-style="western"><surname>Licciardi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Steer</surname><given-names>AC</given-names></string-name>. <article-title>Correlates of protection for M protein-based vaccines against group A Streptococcus.</article-title><source>J Immunol Res</source>. <year>2015</year>;<volume>2015</volume>:<elocation-id>167089</elocation-id>. <pub-id pub-id-type="doi">10.1155/2015/167089</pub-id><pub-id pub-id-type="pmid">26101780</pub-id><pub-id pub-id-type="pmcid">PMC4458553</pub-id></mixed-citation></ref><ref id="R21"><label>21. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lassoued</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Assad</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Ouldali</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Caseris</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mariani</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Birgy</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>Unexpected increase in invasive group A streptococcal infections in children after respiratory viruses outbreak in France: a 15-year time-series analysis.</article-title><source>Open Forum Infect Dis</source>. <year>2023</year>;<volume>10</volume>:<elocation-id>ofad188</elocation-id>. <pub-id pub-id-type="doi">10.1093/ofid/ofad188</pub-id><pub-id pub-id-type="pmid">37180594</pub-id><pub-id pub-id-type="pmcid">PMC10167988</pub-id></mixed-citation></ref><ref id="R22"><label>22. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>de Gier</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Vlaminckx</surname><given-names>BJM</given-names></string-name>, <string-name name-style="western"><surname>Woudt</surname><given-names>SHS</given-names></string-name>, <string-name name-style="western"><surname>van Sorge</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>van Asten</surname><given-names>L</given-names></string-name>. <article-title>Associations between common respiratory viruses and invasive group A streptococcal infection: A time-series analysis.</article-title><source>Influenza Other Respir Viruses</source>. <year>2019</year>;<volume>13</volume>:<fpage>453</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12658</pub-id><pub-id pub-id-type="pmid">31237087</pub-id><pub-id pub-id-type="pmcid">PMC6692538</pub-id></mixed-citation></ref><ref id="R23"><label>23. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mariani</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gentili</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pulcinelli</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Martino</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Valentini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Buonsenso</surname><given-names>D</given-names></string-name>. <article-title>State of the art of invasive group A streptococcus infection in children: a scoping review of the literature with a focus on predictors of invasive infection.</article-title><source>Children (Basel)</source>. <year>2023</year>;<volume>10</volume>:<fpage>1472</fpage>. <pub-id pub-id-type="doi">10.3390/children10091472</pub-id><pub-id pub-id-type="pmid">37761433</pub-id><pub-id pub-id-type="pmcid">PMC10528266</pub-id></mixed-citation></ref><ref id="R24"><label>24. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gregory</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Okaro</surname><given-names>JO</given-names></string-name>, <string-name name-style="western"><surname>Reingold</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Herlihy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Petit</surname><given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>Invasive group A streptococcal infections in 10 US states.</article-title><source>JAMA</source>. <year>2025</year>;<volume>333</volume>:<fpage>1498</fpage>&#8211;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2025.0910</pub-id><pub-id pub-id-type="pmid">40193120</pub-id><pub-id pub-id-type="pmcid">PMC11976646</pub-id></mixed-citation></ref><ref id="R25"><label>25. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>McMillan</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Dr&#232;ze</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Vu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bessen</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Guglielmini</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Steer</surname><given-names>AC</given-names></string-name>, <etal>et al.</etal><article-title>Updated model of group A <italic toggle="yes">Streptococcus</italic> M proteins based on a comprehensive worldwide study.</article-title><source>Clin Microbiol Infect</source>. <year>2013</year>;<volume>19</volume>:<fpage>E222</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/1469-0691.12134</pub-id><pub-id pub-id-type="pmid">23464795</pub-id><pub-id pub-id-type="pmcid">PMC4568957</pub-id></mixed-citation></ref><ref id="R26"><label>26. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cohen</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ashman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Taha</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Varon</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Angoulvant</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Levy</surname><given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?</article-title><source>Infect Dis Now</source>. <year>2021</year>;<volume>51</volume>:<fpage>418</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.idnow.2021.05.004</pub-id><pub-id pub-id-type="pmid">33991720</pub-id><pub-id pub-id-type="pmcid">PMC8114587</pub-id></mixed-citation></ref><ref id="R27"><label>27. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Finn</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Penfound</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Salehi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ogega</surname><given-names>CO</given-names></string-name>, <string-name name-style="western"><surname>Dold</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Plante</surname><given-names>O</given-names></string-name>, <etal>et al.</etal><article-title>Immunogenicity of a 30-valent M protein mRNA group A <italic toggle="yes">Streptococcus</italic> vaccine.</article-title><source>Vaccine</source>. <year>2024</year>;<volume>42</volume>:<elocation-id>126205</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2024.126205</pub-id><pub-id pub-id-type="pmid">39141987</pub-id></mixed-citation></ref><ref id="R28"><label>28. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shulman</surname><given-names>ST</given-names></string-name>, <string-name name-style="western"><surname>Tanz</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Dale</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Beall</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kabat</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kabat</surname><given-names>K</given-names></string-name>, <etal>et al.</etal>; <collab>North American Streptococcal Pharyngitis Surveillance Group</collab>. <article-title>Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates.</article-title><source>Clin Infect Dis</source>. <year>2009</year>;<volume>49</volume>:<fpage>78</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1086/599344</pub-id><pub-id pub-id-type="pmid">19480575</pub-id></mixed-citation></ref><ref id="R29"><label>29. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ram&#237;rez de Arellano</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Saavedra-Lozano</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Villal&#243;n</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jov&#233;-Blanco</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Grandioso</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sotelo</surname><given-names>J</given-names></string-name>, <etal>et al.</etal>; <collab>Spanish PedGAS-Net/CIBERINFEC GAS Study Group</collab>. <article-title>Clinical, microbiological, and molecular characterization of pediatric invasive infections by <italic toggle="yes">Streptococcus pyogenes</italic> in Spain in a context of global outbreak.</article-title><source>mSphere</source>. <year>2024</year>;<volume>9</volume>:<elocation-id>e0072923</elocation-id>. <pub-id pub-id-type="doi">10.1128/msphere.00729-23</pub-id><pub-id pub-id-type="pmid">38440985</pub-id><pub-id pub-id-type="pmcid">PMC10964401</pub-id></mixed-citation></ref><ref id="R30"><label>30. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gouveia</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bajanca-Lavado</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Mamede</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ara&#250;jo Carvalho</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Melo-Cristino</surname><given-names>J</given-names></string-name>, <etal>et al.</etal>; <collab>Portuguese Group for the Study of Streptococcal Infections</collab>; <collab>Portuguese Study Group of Pediatric Invasive Streptococcal Disease</collab>; <collab>Portuguese Study Group of Paediatric Invasive Streptococcal Disease</collab>. <article-title>Sustained increase of paediatric invasive <italic toggle="yes">Streptococcus pyogenes</italic> infections dominated by M1<sub>UK</sub> and diverse <italic toggle="yes">emm</italic>12 isolates, Portugal, September 2022 to May 2023.</article-title><source>Euro Surveill</source>. <year>2023</year>;<volume>28</volume>:<elocation-id>2300427</elocation-id>.<pub-id pub-id-type="pmid">37676143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2023.28.36.2300427</pub-id><pub-id pub-id-type="pmcid">PMC10486195</pub-id></mixed-citation></ref><ref id="R31"><label>31. </label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Abo</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Oliver</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>McMinn</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Osowicki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>JE</given-names></string-name>, <etal>et al.</etal><article-title>Increase in invasive group A streptococcal disease among Australian children coinciding with northern hemisphere surges.</article-title><source>Lancet Reg Health West Pac</source>. <year>2023</year>;<volume>41</volume>:<elocation-id>100873</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.lanwpc.2023.100873</pub-id><pub-id pub-id-type="pmid">38223399</pub-id><pub-id pub-id-type="pmcid">PMC10786649</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>